nach oben

Rheumatology International

Erschienen in:

01.09.2007 | Original Article

Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis

verfasst von: Manathip Osiri, Pirom Kamolratanakul, Andreas Maetzel, Peter Tugwell

Erschienen in: Rheumatology International | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

The objective was to assess the cost-effectiveness of various DMARDs compared with antimalarials (AM) for rheumatoid arthritis (RA) treatment. The data on disease activity, functional status and societal costs were collected from a 1-year cohort of 152 patients with RA receiving at least one DMARD for ≥ 6 months. Incremental cost effectiveness ratio (ICER) was calculated from the societal costs of DMARD treatment compared with AM per one unit of HAQ improvement. All costs were presented in 2001 US dollars. Mean (SD) societal cost of AM treatment was US$ 2,285 (1,154) per patient per year. MTX + AM was less costly and more effective than AM, as the ICER of this combination would save US$ 834 per 1 U of HAQ improvement. MTX + SSZ, leflunomide, and triple therapy (AM + MTX + SSZ) were more effective than AM with additional costs. RA treatment with non MTX-based DMARDs was not cost-effective.

Kvien TK (2004) Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 22(suppl 1):1–12PubMed

Meenan RF, Yelin EH, Henke CJ et al (1978) The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum 21:827–833PubMedCrossRef

Meenan RF, Yelin EH, Nevitt M, Epstein WV (1981) The impact of chronic disease. A sociomedical profile of rheumatoid arthritis. Arthritis Rheum 24:544–549PubMedCrossRef

Lubeck DP, Spitz PW, Fries JF et al (1986) A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum 29:488–493PubMedCrossRef

van Jaarsveld CH, Jacobs JW, Schrijvers AJ et al (1998) Effects of rheumatoid arthritis on employment and social participation during the first years of disease in the Netherlands. Br J Rheumatol 37:848–853PubMedCrossRef

Yelin E, Wanke LA (1999) An assessment of the annual and long-term direct costs of rheumatoid arthritis. The impact of poor function and functional decline. Arthritis Rheum 42:1209–1218PubMedCrossRef

Michaud K, Messer J, Choi HK, Wolfe F (2003) Direct medical costs and their predictors in patients with rheumatoid arthritis. Arthritis Rheum 48:2750–2762PubMedCrossRef

Merkesdal S, Ruof J, Schoffski O et al (2001) Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum 44:528–534PubMedCrossRef

Lajas C, Abasolo L, Bellajdel B et al (2003) Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 49:64–70PubMedCrossRef

10.

Pugner KM, Scott DI, Holmes JW, Hieke K (2000) The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum 29:305–320PubMedCrossRef

11.

Cooper NJ (2000) Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 39:28–33PubMedCrossRef

12.

Suarez-Almazor ME, Osiri M, Emery P, Ottawa Methods Group (2004) Rheumatoid arthritis. In: Tugwell P, Shea B, Boers M et al (eds) Evidence-based rheumatology. BMJ Publishing Group, London, pp 243–282

13.

Gabriel SE, Coyle D, Moreland LW (2001) A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics 19:715–728PubMedCrossRef

14.

Thompson MS, Read JL, Hutchings HC et al (1988) The cost effectiveness of auranofin: results of a randomized clinical trial. J Rheumatol 15:35–42PubMed

15.

Borg G, Allander E, Goobar JE (1990) Disease-modifying antirheumatic drug therapy: an expensive therapy despite inexpensive drugs. Scand J Rheumatol 19:115–121PubMed

16.

Prashker MJ, Meenan RF (1995) The total costs of drug therapy for rheumatoid arthritis. Arthritis Rheum 38:318–325PubMedCrossRef

17.

Kavanaugh A, Heudebert G, Cush J, Jain R (1996) Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 25:297–307PubMedCrossRef

18.

Anis AH, Tugwell PX, Wells GA, Stewart DG (1996) A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. J Rheumatol 23:609–613PubMed

19.

Verhoeven AC, Bibo JC, Boers M et al (1998) Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. Br J Rheumatol 37:1102–1109PubMedCrossRef

20.

Choi HK, Seeger JD, Kuntz KM (2000) A cost-effectiveness analysis of treatment options for methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 43:2316–2327PubMedCrossRef

21.

Maetzel A, Strand V, Tugwell P et al (2002) Economic comparison of leflunomide and methotrexate in patients with rheumatoid arthritis: an evaluation based on a 1-year randomized controlled trial. Pharmacoeconomics 20:61–70PubMedCrossRef

22.

Maetzel A, Strand V, Tugwell P et al (2002) Cost effectiveness of adding leflunomide to a 5-year strategy of conventional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Rheum 47:655–661PubMedCrossRef

23.

Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:15–24CrossRef

24.

Osiri M, Deesomchok U, Tugwell P (2001) Evaluation of functional ability of Thai patients with rheumatoid arthritis by the use of a Thai version of the health assessment questionnaire. Rheumatology 40:555–558PubMedCrossRef

25.

Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145PubMedCrossRef

26.

Heston A, Summers R, Aten B (2002) Penn World Table version 6.1. Center for International Comparisons at the University of Pennsylvania (CICUP). <http://pwt.econ.upenn.edu>

27.

American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) Guidelines for the management of rheumatoid arthritis: 2002 update Arthritis Rheum 46:328–346CrossRef

28.

Carmichael SJ, Beal J, Day RO, Tett SE (2002) Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol 29:2077–2083PubMed

29.

O’Dell JR, Haire CE, Erikson N et al (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334:1287–1291PubMedCrossRef

30.

O’Dell JR, Haire CE, Erikson N et al (1996) Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate. J Rheumatol 23(Suppl 44):72–74

31.

O’Dell J, Paulsen G, Haire C et al (1998) Combination DMARD therapy with methotrexate-sulfasalazine-hydroxychlo-roquine in rheumatoid arthritis: continued efficacy with minimal toxicity at 5 years (abstract). Arthritis Rheum 41(Suppl 9):S132

32.

O’Dell JR, Leff R, Paulsen G et al (2002) Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46:1164–1170PubMedCrossRef

33.

Kobelt G, Jonsson L, Young A, Eberhardt K (2003) The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology 42: 326–335PubMedCrossRef

34.

Welsing PM, Severens JL, Hartman M et al (2004) Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 51:964–973PubMedCrossRef

35.

Brennan A, Bansback N, Reynolds A, Conway P (2004) Modeling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology 43:62–72PubMedCrossRef

Titel: Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis
verfasst von: Manathip Osiri
Pirom Kamolratanakul
Andreas Maetzel
Peter Tugwell
Publikationsdatum: 01.09.2007
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 11/2007
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-007-0342-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2007

Activin A suppresses interleukin-1-induced matrix metalloproteinase 3 secretion in human chondrosarcoma cells

The development of pneumomediastinum after pulmonary function testing in a patient with systemic sclerosis

Editorial

Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up

Tender point count and total myalgic score in fibromyalgia: changes over a 28-day period

Transcription regulatory polymorphism −43T>C in the 5′-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Metformin rückt in den Hintergrund

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

Bei Senioren mit Prostatakarzinom auf Anämie achten!

Update Innere Medizin